At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Triamcinolone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)
In Brief
A Phase 2 clinical trial evaluating Triamcinolone and Valchlor 0.016 % Topical Gel for Cutaneous T-cell Lymphoma and 7 related conditions. Completed, enrolled 28 participants across 1 site.
Detailed Summary
This is a two-arm, open-label study that aims to compare the incidence and severity of the most common adverse reactions, particularly contact dermatitis, when Valchlor is used alone or in conjunction with triamcinolone ointment 0.1% in early stage MF subjects (Stage IA and IB) for a period of 4 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous T-cell Lymphoma, Cutaneous T-cell Lymphoma Stage I, Mycosis Fungoides, Folliculotropic Mycosis Fungoides, Granulomatous Slack Skin, Syringotropic Mycosis Fungoides, Mycosis Fungoides Variant, Transformed Mycosis Fungoides
CountriesUnited States
CollaboratorsRochester General Hospital
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
First PostedDec 2017
Primary CompletionAug 2020
Study CompletionDec 2020
TodayJul 2026
First PostedDec 20, 2017
Enrollment StartDec 13, 2017
Primary CompletionAug 3, 2020
Study CompletionDec 13, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.5 years ago
Interventions
Triamcinolonedrug
Apply up to three times daily on select lesions.
Valchlor 0.016 % Topical Geldrug
Apply valchlor nightly on select lesions.